Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 215

1.

Italian real life experience with brentuximab vedotin: results of a large observational study on 40 relapsed/refractory systemic anaplastic large cell lymphoma.

Broccoli A, Pellegrini C, Di Rocco A, Puccini B, Patti C, Gini G, Mannina D, Tani M, Rusconi C, Romano A, Vanazzi A, Botto B, Carlo-Stella C, Hohaus S, Musto P, Mazza P, Molica S, Corradini P, Fama A, Gaudio F, Merli M, Gravetti A, Gritti G, Arcari A, Tosi P, Liberati AM, Pinto A, Pavone V, Gherlinzoni F, Naso V, Volpetti S, Trentin L, Goldaniga MC, Bonfichi M, De Renzo A, Schiavotto C, Spina M, Storti S, Carella AM, Stefoni V, Argnani L, Zinzani PL.

Haematologica. 2017 Aug 3. pii: haematol.2017.171355. doi: 10.3324/haematol.2017.171355. [Epub ahead of print]

2.

Diffusion-weighted whole-body MRI for evaluation of early response in multiple myeloma.

Lacognata C, Crimì F, Guolo A, Varin C, De March E, Vio S, Ponzoni A, Barilà G, Lico A, Branca A, De Biasi E, Gherlinzoni F, Scapin V, Bissoli E, Berno T, Zambello R.

Clin Radiol. 2017 Jun 3. pii: S0009-9260(17)30180-0. doi: 10.1016/j.crad.2017.05.004. [Epub ahead of print]

PMID:
28587715
3.

Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma.

Pellegrini C, Broccoli A, Pulsoni A, Rigacci L, Patti C, Gini G, Mannina D, Tani M, Rusconi C, Romano A, Vanazzi A, Botto B, Santoro A, Hoaus S, Rigolin GM, Musto P, Mazza P, Molica S, Corradini P, Fama A, Gaudio F, Merli M, Ronconi F, Gritti G, Vallisa D, Tosi P, Liberati AM, Pinto A, Pavone V, Gherlinzoni F, Bianchi MP, Volpetti S, Trentin L, Goldaniga MC, Bonfichi M, De Renzo A, Schiavotto C, Spina M, Carella AM, Stefoni V, Argnani L, Zinzani PL.

Oncotarget. 2017 May 23. doi: 10.18632/oncotarget.18114. [Epub ahead of print]

4.

The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.

Castagnetti F, Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F, Vigneri P, Abruzzese E, Rossi G, Rupoli S, Cavazzini F, Martino B, Orlandi E, Pregno P, Annunziata M, Usala E, Tiribelli M, Sica S, Bonifacio M, Fava C, Gherlinzoni F, Bocchia M, Soverini S, Bochicchio MT, Cavo M, Giovanni M, Saglio G, Pane F, Baccarani M, Rosti G; GIMEMA CML Working Party.

Am J Hematol. 2017 Aug;92(8):797-805. doi: 10.1002/ajh.24774. Epub 2017 May 30.

PMID:
28466557
5.

Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories.

Perricone M, Palandri F, Ottaviani E, Angelini M, Bagli L, Bellesia E, Donati M, Gemmati D, Zucchini P, Mancini S, Marchica V, Trubini S, De Matteis G, Di Zacomo S, Favarato M, Fioroni A, Bolzonella C, Maccari G, Navaglia F, Gatti D, Toffolatti L, Orlandi L, Laloux V, Manfrini M, Galieni P, Giannini B, Tieghi A, Barulli S, Serino ML, Maccaferri M, Scortechini AR, Giuliani N, Vallisa D, Bonifacio M, Accorsi P, Salbe C, Fazio V, Gusella M, Toffoletti E, Salvucci M, Svaldi M, Gherlinzoni F, Cassavia F, Orsini F, Martinelli G.

Oncotarget. 2017 May 16;8(20):32608-32617. doi: 10.18632/oncotarget.15940.

6.

Observational retrospective study of vascular modulator changes during treatment in essential thrombocythemia.

Piccin A, Steurer M, Feistritzer C, Murphy C, Eakins E, Van Schilfgaarde M, Corvetta D, Di Pierro AM, Pusceddu I, Marcheselli L, Gambato R, Langes M, Veneri D, Perbellini O, Pacquola E, Gottardi M, Gherlinzoni F, Mega A, Tauber M, Mazzoleni G, Piva E, Plebani M, Krampera M, Gastl G.

Transl Res. 2017 Jun;184:21-34. doi: 10.1016/j.trsl.2017.02.001. Epub 2017 Feb 14.

PMID:
28259616
7.

Two novel missense mutations in EPOR gene causes erythrocytosis in two unrelated patients.

Peroni E, Bertozzi I, Gherlinzoni F, Stefani PM, Lombardi A, Biagetti G, Fabris F, Randi ML.

Br J Haematol. 2016 Dec 16. doi: 10.1111/bjh.14486. [Epub ahead of print] No abstract available.

PMID:
27982410
8.

Adrenomedullin in the growth modulation and differentiation of acute myeloid leukemia cells.

Di Liddo R, Bridi D, Gottardi M, De Angeli S, Grandi C, Tasso A, Bertalot T, Martinelli G, Gherlinzoni F, Conconi MT.

Int J Oncol. 2016 Apr;48(4):1659-69. doi: 10.3892/ijo.2016.3370. Epub 2016 Feb 2.

PMID:
26847772
9.

Psychological screening of onco-hematologic inpatients: Distress Thermometer administration.

Bellè M, Muzzatti B, Tomas M, Gherlinzoni F.

Tumori. 2016 Mar-Apr;102(2):178-83. doi: 10.5301/tj.5000440. Epub 2015 Oct 5.

PMID:
26439150
10.

Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy.

Lazzarotto D, Candoni A, Nadali G, Pavan L, Lessi F, Mosna F, Simeone E, Ventura G, Gherlinzoni F, Semenzato G, Pizzolo G, Fanin R.

Eur J Haematol. 2016 Jun;96(6):586-92. doi: 10.1111/ejh.12635. Epub 2015 Aug 17.

PMID:
26186084
11.

Prognostic value of Positron Emission Tomography/Computed Tomography in patients with Lymphoma treated with autologous stem cell transplantation (ASCT) for relapsed/refractory or high risk disease.

Stefani PM, Salvadori U, Gottardi M, Bissoli S, Chierichetti F, Gherlinzoni F.

Q J Nucl Med Mol Imaging. 2015 Jun 23. [Epub ahead of print]

PMID:
26101430
12.

Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.

Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, Abruzzese E, Martino B, Levato L, Intermesoli T, Pregno P, Rossi G, Gherlinzoni F, Leoni P, Cavazzini F, Venturi C, Soverini S, Testoni N, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party.

Leukemia. 2015 Sep;29(9):1823-31. doi: 10.1038/leu.2015.152. Epub 2015 Jun 19.

PMID:
26088952
13.

Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.

Mosna F, Papayannidis C, Martinelli G, Di Bona E, Bonalumi A, Tecchio C, Candoni A, Capelli D, Piccin A, Forghieri F, Bigazzi C, Visani G, Zambello R, Zanatta L, Volpato F, Paolini S, Testoni N, Gherlinzoni F, Gottardi M.

Am J Hematol. 2015 Jun;90(6):515-23. doi: 10.1002/ajh.24000. Epub 2015 Apr 1.

14.

Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia.

Piccin A, Steurer M, Mitterer M, Blöchl EM, Marcheselli L, Pusceddu I, Marabese A, Bertozzi I, Corvetta D, Randi ML, Elli E, Pogliani EM, Veneri D, Perbellini O, Krampera M, Pacquola E, Gottardi M, Tiribelli M, Guella A, Innella B, Vivaldi P, De Biasi E, Sancetta R, Rocconi R, Bassan R, Gherlinzoni F, Pizzolo G, Gastl G, Cortelazzo S.

Intern Emerg Med. 2015 Jun;10(4):451-60. doi: 10.1007/s11739-015-1186-8. Epub 2015 Jan 14.

PMID:
25585678
15.

Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma.

Visani G, Stefani PM, Capria S, Malerba L, Galieni P, Gaudio F, Specchia G, Meloni G, Gherlinzoni F, Gonella R, Gobbi M, Santoro A, Ferrara F, Rocchi M, Ocio EM, Caballero MD, Loscocco F, Isidori A.

Blood. 2014 Nov 6;124(19):3029-31. doi: 10.1182/blood-2014-08-596668. No abstract available.

16.

Differences among young adults, adults and elderly chronic myeloid leukemia patients.

Castagnetti F, Gugliotta G, Baccarani M, Breccia M, Specchia G, Levato L, Abruzzese E, Rossi G, Iurlo A, Martino B, Pregno P, Stagno F, Cuneo A, Bonifacio M, Gobbi M, Russo D, Gozzini A, Tiribelli M, de Vivo A, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G; GIMEMA CML Working Party.

Ann Oncol. 2015 Jan;26(1):185-92. doi: 10.1093/annonc/mdu490. Epub 2014 Oct 30.

PMID:
25361995
17.

MGMT promoter methylation and correlation with protein expression in primary central nervous system lymphoma.

Toffolatti L, Scquizzato E, Cavallin S, Canal F, Scarpa M, Stefani PM, Gherlinzoni F, Dei Tos AP.

Virchows Arch. 2014 Nov;465(5):579-86. doi: 10.1007/s00428-014-1622-6. Epub 2014 Jul 17.

PMID:
25031012
18.

Prognostic significance of circulating and endothelial progenitor cell markers in type 2 diabetic foot.

Sambataro M, Seganfreddo E, Canal F, Furlan A, Del Pup L, Niero M, Paccagnella A, Gherlinzoni F, Dei Tos AP.

Int J Vasc Med. 2014;2014:589412. doi: 10.1155/2014/589412. Epub 2014 Feb 3.

19.

Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group.

Gronchi A, Colombo C, Le Péchoux C, Dei Tos AP, Le Cesne A, Marrari A, Penel N, Grignani G, Blay JY, Casali PG, Stoeckle E, Gherlinzoni F, Meeus P, Mussi C, Gouin F, Duffaud F, Fiore M, Bonvalot S; ISG and FSG.

Ann Oncol. 2014 Mar;25(3):578-83. doi: 10.1093/annonc/mdt485. Epub 2013 Dec 9.

20.

EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia.

Tiribelli M, Bonifacio M, Calistri E, Binotto G, Maino E, Marin L, Guardalben E, Branca A, Gherlinzoni F, Semenzato G, Sancetta R, Pizzolo G, Fanin R.

Leuk Res. 2013 Nov;37(11):1457-60. doi: 10.1016/j.leukres.2013.07.037. Epub 2013 Aug 11.

PMID:
23993428

Supplemental Content

Loading ...
Support Center